Sareum Holdings PLC US Patent Granted for SDC-1802 TYK2/JAK1 Inhibitor (3573O)
07 Octubre 2021 - 4:42AM
UK Regulatory
TIDMSAR
RNS Number : 3573O
Sareum Holdings PLC
07 October 2021
SAREUM HOLDINGS PLC
("Sareum" or "the Company")
US Patent Granted for Sareum's SDC-1802 TYK2/JAK1 Inhibitor
Cambridge, UK, 7 October 2021 - Sareum Holdings plc (AIM: SAR),
the specialist drug development company delivering targeted small
molecule therapeutics to improve the treatment of cancer and
autoimmune diseases, announces that, further to its announcement of
30 July 2021, the United States Patent and Trademark Office has now
formally approved its patent i n respect of an invention associated
with Sareum's proprietary SDC-1802 TYK2/JAK1 Kinase Inhibitor
Programme (the "SDC-1802 Programme").
The patent (US 11,154,539) will grant on 26 October 2021 and
will protect the SDC-1802 molecule and pharmaceutical preparations
thereof as a therapeutic to treat cancer selected from pancreatic,
colorectal and kidney cancers, melanoma, and B-cell lymphoma by
inhibiting TYK2 kinase. This programme is in preclinical
development.
Sareum's CSO, Dr John Reader, commented :
"We are pleased to confirm the grant of this US patent for
SDC-1802, adding another layer of protection around this promising
candidate in key territories. Our SDC-1802 programme is in
preclinical development currently and we are designing the
translational studies needed to define the optimal cancer
application prior to completing toxicology and manufacturing
studies. We look forward to providing further updates on progress
as we achieve key milestones."
For further information, please contact:
Sareum Holdings plc
Tim Mitchell, CEO 01223 497 700
Strand Hanson Limited (Nominated
Adviser)
James Dance / James Bellman 020 7409 3494
Hybridan LLP (Nominated Broker)
Claire Noyce 020 3764 2341
MEDiSTRAVA Consulting (Financial
PR)
Mark Swallow / David Dible 020 7638 9571
About Sareum
Sareum is a specialist drug development company delivering
targeted small molecule therapeutics to improve the treatment of
cancer and autoimmune diseases. The Company aims to generate value
through licensing its candidates to international pharmaceutical
and biotechnology companies at the preclinical or early clinical
trials stage.
Sareum is advancing internal programmes focused on distinct dual
tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through
preclinical development as therapies for autoimmune diseases,
including the 'cytokine storm' immune system overreaction to
Covid-19 and other viral infections, (SDC-1801) and cancer
immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage
oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets
cancer cell replication and DNA damage repair mechanisms.
Preliminary Phase 2 and comprehensive preclinical data suggest
SRA737 may have broad application in combination with other
oncology and immune-oncology drugs in genetically defined
patients.
SRA737 was discovered and initially developed by scientists at
The Institute of Cancer Research in collaboration with Sareum, and
with funding from Sareum and Cancer Research UK. SRA737 was
licensed by CRT Pioneer Fund (CPF) to Sierra Oncology Inc. Sierra
continues to explore options that would enable the development of
SRA737 to advance.
Sareum Holdings plc is listed on the AIM market of the London
Stock Exchange, trading under the ticker SAR. For further
information, please visit the Company's website at
www.sareum.com
- Ends -
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCEANEXELFFFEA
(END) Dow Jones Newswires
October 07, 2021 05:42 ET (09:42 GMT)
Sareum (LSE:SAR)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Sareum (LSE:SAR)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024